Ascelia Pharma AB
STO:ACE

Watchlist Manager
Ascelia Pharma AB Logo
Ascelia Pharma AB
STO:ACE
Watchlist
Price: 3.125 SEK -3.7%
Market Cap: 396.5m SEK

Ascelia Pharma AB
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Ascelia Pharma AB
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Ascelia Pharma AB
STO:ACE
Free Cash Flow
-kr69.4m
CAGR 3-Years
19%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Free Cash Flow
kr322m
CAGR 3-Years
7%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Free Cash Flow
kr235.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Free Cash Flow
kr468m
CAGR 3-Years
8%
CAGR 5-Years
10%
CAGR 10-Years
13%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Free Cash Flow
kr4.2B
CAGR 3-Years
9%
CAGR 5-Years
6%
CAGR 10-Years
31%
BioArctic AB
STO:BIOA B
Free Cash Flow
-kr343m
CAGR 3-Years
-33%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ascelia Pharma AB
Glance View

Market Cap
399.7m SEK
Industry
Biotechnology

Ascelia Pharma AB engages in the research and development of pharmaceutical products for the treatment of cancer and cancer-related diseases. The company is headquartered in Malmo, Skane. The company went IPO on 2019-03-13. The firm identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The firm's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. The company has completed phase I of clinical studies.

ACE Intrinsic Value
5.341 SEK
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Ascelia Pharma AB's Free Cash Flow?
Free Cash Flow
-69.4m SEK

Based on the financial report for Sep 30, 2025, Ascelia Pharma AB's Free Cash Flow amounts to -69.4m SEK.

What is Ascelia Pharma AB's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
2%

Over the last year, the Free Cash Flow growth was -16%. The average annual Free Cash Flow growth rates for Ascelia Pharma AB have been 19% over the past three years , 2% over the past five years .

Back to Top